<DOC>
	<DOCNO>NCT00864201</DOCNO>
	<brief_summary>The primary objective exploratory study evaluate effect bosentan hemodynamics ( via cardiac catheterization ) exercise patient Pulmonary Arterial Hypertension ( PAH ) abnormal hemodynamics exercise normal hemodynamics rest . The author hypothesize early treatment may change course disease progression improve hemodynamics exercise , thus delay disease progression .</brief_summary>
	<brief_title>A Study Evaluate Use Bosentan Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Men woman ≥ 18 year age For female patient , nonpregnant woman surgically sterile , postmenopausal document infertility ( 50 year age amenorrheic least 1 year ) , childbearing potential use one follow method contraception : Barriertype device ( e.g. , condom , diaphragm ) use ONLY combination spermicide . A doublebarrier method recommend . Intrauterine device ( IUDs ) Oral contraceptive , use combination barrier method Body weight 40 kg high Patients diagnose connective tissue disease Hemodynamics rest , base cardiac catheterization , follow : Mean pulmonary arterial pressure ( mPAP ) : 18 25 mmHg PCWP ≤ 15 mmHg Hemodynamics exercise , base cardiac catheterization , follow : mPAP &gt; 30 mmHg Provide write informed consent PAH associate condition Severe obstructive lung disease : FEV1∕ FVC &lt; 0.5 Total lung capacity &lt; 60 % normal predict value Unable unwilling cardiac catheterization procedure Acute chronic impairment ( dyspnea ) , limit ability comply study requirement ( 6MWT ) Psychotic , addictive disorder limit ability provide inform consent comply study requirement Moderate severe hepatic impairment , i.e. , ChildPugh Class B C AST ∕or ALT &gt; 3 time uln Hemoglobin concentration &gt; 25 % low limit normal Systolic blood pressure &lt; 85 mm Hg Pregnancy breastfeed Treatment plan treatment another investigational drug Treatment endothelin receptor antagonist , phosphodiesterase type 5 inhibitor , prostanoids ( exclude acute administration catheterization procedure test vascular reactivity ) within 2 month inclusion Treatment calcineurininhibitors ( i.e. , cyclosporine A tacrolimus ) , fluconazole , glibenclamide ( glyburide ) within 1 week study start ; Known hypersensitivity bosentan excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>